General Cancer FAQs

Cancer staging describes how much cancer is in the body and how far it has spread. The most widely used system is the system Tumor size, Node involvement, Metastasis (TNM ) system, which feeds into stage groupings.

Stage 0 — In situ — abnormal cells present but haven't invaded surrounding tissue (e.g., DCIS in the breast)

Stage 1 — Small tumor, localized to the organ of origin, no lymph node involvement

Stage II — Larger tumor and/or some nearby lymph node involvement, but still relatively localized

Stage III — More extensive local/regional spread; may involve multiple nearby lymph nodes or adjacent structures

Stage IV — Metastatic — cancer has spread to distant organs (e.g., liver, lungs, brain, bone)

Important nuances:

• Stages are further broken into sub-stages (IA, IB, IIA, IIB, etc.)
• Clinical staging is based on what is seen and felt before surgery (imaging, physical exam)
• Pathological staging is based on what is found in the tissue removed during surgery — these can differ, as discussed in Manta Cares nurse call with Beverly, where her clinical and pathological stages needed clarification
• For lung cancer, Stage 4 is divided into 4A (spread within the chest) and 4B (distant spread) — this distinction matters for prognosis and treatment options
• Staging is not destiny — treatment, response, and individual biology all matter

No — not all cancers are purely genetic. There are two important concepts:

Hereditary (germline) cancer: A mutation is inherited from a parent, is present in every cell of your body, and significantly raises lifetime cancer risk. These include:

• BRCA1/BRCA2 — significantly elevated risk for breast, ovarian, pancreatic, prostate cancer
• Lynch syndrome — elevated risk for colorectal, uterine, and other cancers
• PALB2, CHEK2, ATM — elevated breast cancer risk
• TP53 (Li-Fraumeni syndrome), PTEN (Cowden syndrome), and others

Somatic mutations: Acquired mutations that occur during a person's lifetime in specific cancer cells — these are not inherited and not in every cell. EGFR mutations in lung cancer, for example, are typically somatic.

Who should consider hereditary genetic testing (germline testing)?

• Breast cancer diagnosed at a young age (under 50)
• Male breast cancer at any age
• Triple negative breast cancer
• Multiple family members with breast, ovarian, pancreatic, or prostate cancer
• Personal or family history of ovarian cancer
• Ashkenazi Jewish ancestry (higher BRCA prevalence)
• Family member known to carry a BRCA or other hereditary mutation

For lung cancer: Somatic biomarker testing of the tumor tissue (EGFR, ALK, ROS1, KRAS, PD-L1, etc.) is not about family inheritance — it's about identifying targetable drivers in the tumor. As Gloria and Kelley emphasized on the Manta Cares platform, biomarker testing is essential, and patients should actively ask their oncologist about it if it hasn't been done.

Manta Cares patients also noted that genetic testing results heavily influenced surgical decisions — for example, a BRCA2
mutation influenced one patient's choice of bilateral mastectomy.

Both are cancer treatments, but they work very differently:

Chemotherapy
How it Works — Drugs that travel through the bloodstream and kill rapidly dividing cells throughout the body
Reach — Systemic — treats cancer cells anywhere in the body
Delivery — IV infusion, oral pills, or injections
Side Effects — Hair loss, nausea/vomiting, fatigue, increased infection risk, neuropathy, mucositis
When Used — To shrink tumors before surgery, eliminate remaining cells after surgery, or treat systemic/metastatic disease

Radiation Therapy
How it Works — High-energy beams (X-rays, protons) targeted at a specific area to damage cancer cell DNA
Reach — Local — targets a defined area
Delivery — External beam (machine outside the body) or internal (brachytherapy — radioactive seeds placed inside)
Side Effects — Skin changes/burns at the treatment site, fatigue, localized pain, specific effects depending on the area treated (e.g., swallowing difficulty for throat radiation)
When Used — After lumpectomy to eliminate remaining local cancer; for locally advanced tumors; palliative purposes

They are often used together or sequentially. The choice depends on cancer type, stage, and individual patient factors such as cardiac history, as one Manta Cares patient with a Cardiac Calcium Score >1000 had to carefully weigh the cardiotoxic risk of chemotherapy against her cancer treatment needs.

Both are taxane chemotherapy drugs that work by stabilizing microtubules inside cells, preventing cancer cells from dividing. They are closely related but have notable differences:

Taxol (Paclitaxel)
Drug Class — Taxane
Administration — IV infusion, typically weekly or every 3 weeks
Common Uses — Breast, ovarian, lung, other cancers
Neuropathy Risk — Significant — peripheral neuropathy (tingling/numbness in hands and feet) is a major concern
Hair Loss — Hair loss occurs, but hair typically regrows more reliably after treatment
Fluid Retention — Less prominent
Nail Changes — Possible

Taxotere (Docetaxel)
Drug Class — Taxane
Administration — IV infusion, typically every 3 weeks
Common Uses — Breast, lung, prostate, gastric, head & neck cancers
Neuropathy Risk — Also causes neuropathy, but the pattern may differ
Hair Loss — Hair loss is also common; some patients experience permanent or prolonged hair thinning — this is one meaningful distinction
Fluid Retention — Can cause significant fluid retention and edema — steroids are given pre-treatment to mitigate
Nail Changes — Common — nail discoloration, separation

Notably, Manta Cares patient Kristan mentioned she hadn't heard of the term "Taxotere" or "docetaxel" outside of the Manta Cares platform, while Paclitaxel/Taxol felt familiar — a reminder that drug names can be confusing when patients know them by one name but see another on their treatment plan.

Cold capping (scalp cooling) is a method used to reduce chemotherapy-related hair loss. A cold cap or cooling system is worn during chemotherapy infusions to constrict blood vessels in the scalp, reducing the amount of chemotherapy that reaches hair follicles.

Does it work?

• Yes — it has been shown to reduce hair loss in some patients, particularly for taxane-based regimens (Taxol, Taxotere)
• It is most effective for single-agent chemotherapy and for certain drug combinations; it is less effective for regimens that include doxorubicin (Adriamycin/the "A" in AC)
• Studies suggest that approximately 50% of patients who use scalp cooling retain enough hair to avoid the need for a wig, but results vary significantly by individual and chemotherapy regimen
• Cold capping is less effective when dose-dense regimens are used

What to know practically:

• It requires wearing the cap for a set period before, during, and after each infusion — sometimes several hours total per session
• It can cause headache, discomfort, and a cold sensation
• Some cancer centers offer their own cooling systems; others require patients to rent the Paxman or Dignicap devices
• Insurance coverage varies widely — it is worth checking

Hair loss remains one of the most emotionally impactful side effects of chemotherapy. As Chloe at Manta Cares acknowledged: "It's what patients really care about, and it's often things that doctors and nurses fail to bring up." Cold capping is one valid option to discuss with your oncologist before starting treatment.

Follow-up schedules vary by cancer type and stage, but here is a typical pattern for patients with early-stage cancer:

For breast cancer (common example):

• Years 1–2 post-treatment: Every 3–6 months
• Years 3–5: Every 6 months
• After 5 years: Annually (or sometimes back to 6-month intervals if on endocrine therapy)

For lung cancer:

• More frequent surveillance CT scans, especially in the first 2 years
• Typically every 3–6 months for imaging in years 1–2; annually thereafter

What follow-up typically includes:

• Physical examination
• Discussion of any new symptoms
• Imaging (mammograms for breast cancer, CT scans for lung cancer) on a scheduled basis
• Blood tests for tumor markers in some cancer types
• Ongoing medication management if on endocrine therapy, TKIs, or other maintenance treatments

Manta Cares breast cancer survivor Tami shared that after completing treatment, she only sees her oncologist once a year, primarily to manage her aromatase inhibitor prescription. She described the emotional transition vividly: "You've been seeing all of these people all of this time. And now, all of a sudden... you see your oncologist once a year." This post-treatment transition can feel like a significant loss of support, and it's completely normal.

Many patients remain on long-term oral therapies (tamoxifen, aromatase inhibitors, TKIs for lung cancer) that require ongoing monitoring, so the oncology relationship continues — just less intensively.

Remission means that the signs and symptoms of cancer have decreased or disappeared in response to treatment. There are two types:

• Partial remission: The cancer has decreased significantly (typically by 50% or more) but has not completely disappeared
• Complete remission (complete response): No cancer can be detected by tests, imaging, or physical exam. For some cancers (like TNBC), a pathological complete response (pCR) — no cancer cells found in the removed tissue after neoadjuvant treatment — is a key milestone that predicts better long-term outcomes

What remission is NOT:

• A guarantee that the cancer is gone permanently
• The same as being "cured"

The remission process:

• Can begin during treatment (some patients see a rapid tumor response)
• Is confirmed through imaging, blood markers, and/or pathology
• Requires ongoing surveillance to monitor for any signs of return
• May still involve continuation of maintenance therapy (e.g., aromatase inhibitors, oral TKIs)

The emotional complexity of remission is significant — many patients on the Manta Cares platform describe feeling both relief and heightened anxiety, because the regular contact with the medical team decreases while worry about recurrence persists. This is sometimes called "scanxiety."

Milestones vary by cancer type and are not one-size-fits-all, but commonly recognized markers include:

• End of active treatment — completing chemotherapy, radiation, or surgical recovery
• Pathological complete response (pCR) — for those who received neoadjuvant (pre-surgery) treatment, no residual cancer found in surgery is a major positive milestone
• First clear scan post-treatment — often a powerful emotional moment
• 6-month mark — first follow-up imaging typically happens here
• 1-year cancer-free — a milestone many patients celebrate
• 2-year mark — recurrence risk drops meaningfully for many cancer types after 2 years
• 3-year mark — another significant point; many clinical trials use 3-year disease-free survival as an endpoint
• 5-year mark — traditionally considered a major milestone; for many hormone receptor-positive cancers, 5-year recurrence-free survival is a primary clinical goal
• 10-year mark — for HR+ breast cancer, recurrence risk persists beyond 5 years; the 10-year milestone is increasingly recognized as significant

This is one of the most emotionally loaded questions patients ask. The honest answer is nuanced:

• There is no universal definition of "cancer-free" — it varies by cancer type, stage, and time elapsed
• Most oncologists use the term "no evidence of disease" (NED) rather than "cancer-free" or "cured," because modern testing cannot detect every microscopic cancer cell
• Five years of NED is the most widely cited milestone, after which many (not all) cancers are considered unlikely to recur
• For hormone receptor-positive breast cancer, the risk of late recurrence persists beyond 5 and even 10 years — this is why endocrine therapy is often continued for 7–10 years
• For early-stage TNBC with a pathological complete response, the 5-year NED milestone carries particularly strong prognostic weight
• For lung cancer with EGFR mutations on TKI therapy, patients may remain on treatment indefinitely, as long as there is disease control — "cancer-free" in the traditional sense may not apply in the same way

The preferred framing used by many oncologists and advocated by patient communities (including those on the Manta Cares platform) is to talk about disease-free intervals, recurrence risk percentages, and NED status rather than making absolute "cancer-free" declarations — because these more honestly reflect what is known and preserve realistic hope.